Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Low Grade Lymphoproliferative Disorders
NCT00023764Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2001
- Primary completion
- Mar 2009
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in follicular lymphoma (FL) and mantle cell lymphoma (MCL), sponsored by National Cancer Institute. Primary endpoint: Complete and Partial Response Rate up to 3 years. Started Jun 2001; status: completed.
02
Drugs
bortezomib
03
Conditions
follicular lymphoma (FL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00023764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00023764.